ADVERTISEMENT
Improving Survival Rates Among Patients With NSCLC Using New, Effective Treatment Strategy
Roy S Herbst, MD, PhD, ensign professor of medicine and professor of pharmacology, chief of medical oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses the results of the ADAURA study that examined the use of Tagrisso (osimertinib; AstraZenca) for patients with NSCLC, and highlights how use of Tagrisso showed statistically significant and clinically meaningful improvements in disease-free survival.
Reference:
Herbst RS, Tsuboi M, John T, et al. Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA. J Clin Oncol 38: 2020 (suppl; abstr LBA5). doi: 10.1200/JCO.2020.38.18_suppl.LBA5
Advertisement
Advertisement
Advertisement
Current Issue
Advertisement
Advertisement